Winning in Life Sciences
Navigating a complex industry
In this post-recession era, many global health systems will be impacted by a series of austerity measures. Pricing and re-imbursement pressures, high hurdles for innovation, and the need to demonstrate economic value can only get more severe. Patent expiry, and the lack of new products coming to market, means that life sciences companies will struggle to deliver top-line growth. Companies have re-structured their commercial models to meet the demands of the mature health markets and to focus on value and market access.